Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, California 92121, USA.
J Org Chem. 2010 Jul 2;75(13):4463-71. doi: 10.1021/jo100629z.
We have recently completed the synthesis of 1-[2-(4-cyclobutyl-[1,4]diazepane-1-carbonyl)-4-(3-fluoro-phenoxy)-pyrrolidin-1-yl]-ethanone, a hydroxyproline-based H(3) receptor antagonist, on 100 g scale. The synthesis proceeds through four steps and route selection was driven by a desire to minimize the cost-of-goods. Naturally occurring trans-4-hydroxy-L-proline was chosen as the precursor to the target's core, which necessitated an inversion at both stereogenic centers. The inversions were accomplished through strategic employment of La Rosa's lactone and a late-stage Mitsunobu reaction. A first generation synthesis that employed N-Boc-homopiperazine was improved in a second generation approach wherein homopiperazine was directly desymmetrized. Finally, the water solubility of a key intermediate necessitated the development of a nonextractive workup for the sodium triacetoxyborohydride reduction.
我们最近在 100 克规模上完成了 1-[2-(4-环丁基-[1,4]二氮杂环庚烷-1-羰基)-4-(3-氟-苯氧基)-吡咯烷-1-基]-乙酮的合成,这是一种基于羟脯氨酸的 H(3)受体拮抗剂。该合成通过四个步骤进行,路线选择的驱动力是降低产品成本。天然存在的反式-4-羟基-L-脯氨酸被选为目标物核心的前体,这需要在两个手性中心都进行反转。通过战略性地使用 La Rosa 内酯和后期的 Mitsunobu 反应来实现反转。第一代合成采用 N-Boc-高哌嗪,在第二代方法中得到了改进,其中高哌嗪直接进行了非对称化。最后,由于关键中间体的水溶性,需要开发一种非萃取的工作流程来进行三乙酰氧基硼氢化钠还原。